Admission levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) are Associated with the Development of Severe Complications in Hospitalised COVID-19 Patients: A Prospective Cohort Study
Objective: To examine the association between plasma levels of the soluble urokinase plasminogen activator receptor (suPAR) and the incidence of severe complications of COVID-19. Methods: 403 RT-PCR-confirmed COVID-19 patients were recruited and prospectively followed-up at a major hospital in the U...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-06-01
|
| Series: | International Journal of Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971221003374 |
| _version_ | 1829513520309338112 |
|---|---|
| author | Abderrahim Oulhaj Ahmed R. Alsuwaidi Abubaker Suliman Huda Gasmelseed Shaima Khan Shamma Alawi Yaman Hukan Junu George Fayez Alshamsi Farrukh Sheikh Zahir Osman Eltahir Babiker Juergen Prattes Harald Sourij |
| author_facet | Abderrahim Oulhaj Ahmed R. Alsuwaidi Abubaker Suliman Huda Gasmelseed Shaima Khan Shamma Alawi Yaman Hukan Junu George Fayez Alshamsi Farrukh Sheikh Zahir Osman Eltahir Babiker Juergen Prattes Harald Sourij |
| author_sort | Abderrahim Oulhaj |
| collection | DOAJ |
| description | Objective: To examine the association between plasma levels of the soluble urokinase plasminogen activator receptor (suPAR) and the incidence of severe complications of COVID-19. Methods: 403 RT-PCR-confirmed COVID-19 patients were recruited and prospectively followed-up at a major hospital in the United Arab Emirates. The primary endpoint was time from admission until the development of a composite outcome, including acute respiratory distress syndrome (ARDS), intensive care unit (ICU) admission, or death from any cause. Patients discharged alive were considered as competing events to the primary outcome. Competing risk regression was used to quantify the association between suPAR and the incidence of the primary outcome. Results: 6.2% of patients experienced ARDS or ICU admission, but none died. Taking into account competing risk, the incidence of the primary outcome was 11.5% (95% confidence interval [CI], 6.7–16.3) in patients with suPAR levels >3.91 ng/mL compared to 2.9% (95% CI, 0.4–5.5) in those with suPAR ≤3.91 ng/mL. Also, an increase by 1 ng/mL in baseline suPAR resulted in a 58% rise in the hazard of developing the primary outcome (hazard ratio 1.6, 95% CI, 1.2–2.1, p = 0.003). Conclusion: suPAR has an excellent prognostic utility in predicting severe complications in hospitalised COVID-19 patients. |
| first_indexed | 2024-12-16T13:00:24Z |
| format | Article |
| id | doaj.art-8d5a5a0054b54a4c839a137e2c672ee5 |
| institution | Directory Open Access Journal |
| issn | 1201-9712 |
| language | English |
| last_indexed | 2024-12-16T13:00:24Z |
| publishDate | 2021-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal of Infectious Diseases |
| spelling | doaj.art-8d5a5a0054b54a4c839a137e2c672ee52022-12-21T22:30:51ZengElsevierInternational Journal of Infectious Diseases1201-97122021-06-01107188194Admission levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) are Associated with the Development of Severe Complications in Hospitalised COVID-19 Patients: A Prospective Cohort StudyAbderrahim Oulhaj0Ahmed R. Alsuwaidi1Abubaker Suliman2Huda Gasmelseed3Shaima Khan4Shamma Alawi5Yaman Hukan6Junu George7Fayez Alshamsi8Farrukh Sheikh9Zahir Osman Eltahir Babiker10Juergen Prattes11Harald Sourij12Institute of Public Health, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates; Zayed Center for Health Sciences, United Arab Emirates University, United Arab Emirates; Corresponding author at: Institute of Public Health, College of Medicine and Health Sciences, United Arab Emirates University, PO Box 17666, Al Ain, United Arab Emirates.Department of Paediatrics, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab EmiratesInstitute of Public Health, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab EmiratesAl Ain Hospital, Al Ain, United Arab EmiratesAcademic Affairs Department, Tawam Hospital, Al Ain, United Arab EmiratesAcademic Affairs Department, Tawam Hospital, Al Ain, United Arab EmiratesAcademic Affairs Department, Tawam Hospital, Al Ain, United Arab EmiratesDepartment of Paediatrics, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab EmiratesDepartment of Internal Medicine, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab EmiratesAl Ain Hospital, Al Ain, United Arab EmiratesDivision of Infectious Diseases, Sheikh Shakhbout Medical City in Partnership with Mayo Clinic, Abu Dhabi, United Arab EmiratesDepartment of Internal Medicine, Section of Infectious Diseases and Tropical Medicine, Medical University of Graz, AustriaZayed Center for Health Sciences, United Arab Emirates University, United Arab Emirates; Department of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, AustriaObjective: To examine the association between plasma levels of the soluble urokinase plasminogen activator receptor (suPAR) and the incidence of severe complications of COVID-19. Methods: 403 RT-PCR-confirmed COVID-19 patients were recruited and prospectively followed-up at a major hospital in the United Arab Emirates. The primary endpoint was time from admission until the development of a composite outcome, including acute respiratory distress syndrome (ARDS), intensive care unit (ICU) admission, or death from any cause. Patients discharged alive were considered as competing events to the primary outcome. Competing risk regression was used to quantify the association between suPAR and the incidence of the primary outcome. Results: 6.2% of patients experienced ARDS or ICU admission, but none died. Taking into account competing risk, the incidence of the primary outcome was 11.5% (95% confidence interval [CI], 6.7–16.3) in patients with suPAR levels >3.91 ng/mL compared to 2.9% (95% CI, 0.4–5.5) in those with suPAR ≤3.91 ng/mL. Also, an increase by 1 ng/mL in baseline suPAR resulted in a 58% rise in the hazard of developing the primary outcome (hazard ratio 1.6, 95% CI, 1.2–2.1, p = 0.003). Conclusion: suPAR has an excellent prognostic utility in predicting severe complications in hospitalised COVID-19 patients.http://www.sciencedirect.com/science/article/pii/S1201971221003374COVID-19Urokinase plasminogen activatorAcute respiratory distress syndromeIntensive care admissionAll-cause mortality |
| spellingShingle | Abderrahim Oulhaj Ahmed R. Alsuwaidi Abubaker Suliman Huda Gasmelseed Shaima Khan Shamma Alawi Yaman Hukan Junu George Fayez Alshamsi Farrukh Sheikh Zahir Osman Eltahir Babiker Juergen Prattes Harald Sourij Admission levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) are Associated with the Development of Severe Complications in Hospitalised COVID-19 Patients: A Prospective Cohort Study International Journal of Infectious Diseases COVID-19 Urokinase plasminogen activator Acute respiratory distress syndrome Intensive care admission All-cause mortality |
| title | Admission levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) are Associated with the Development of Severe Complications in Hospitalised COVID-19 Patients: A Prospective Cohort Study |
| title_full | Admission levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) are Associated with the Development of Severe Complications in Hospitalised COVID-19 Patients: A Prospective Cohort Study |
| title_fullStr | Admission levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) are Associated with the Development of Severe Complications in Hospitalised COVID-19 Patients: A Prospective Cohort Study |
| title_full_unstemmed | Admission levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) are Associated with the Development of Severe Complications in Hospitalised COVID-19 Patients: A Prospective Cohort Study |
| title_short | Admission levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) are Associated with the Development of Severe Complications in Hospitalised COVID-19 Patients: A Prospective Cohort Study |
| title_sort | admission levels of soluble urokinase plasminogen activator receptor supar are associated with the development of severe complications in hospitalised covid 19 patients a prospective cohort study |
| topic | COVID-19 Urokinase plasminogen activator Acute respiratory distress syndrome Intensive care admission All-cause mortality |
| url | http://www.sciencedirect.com/science/article/pii/S1201971221003374 |
| work_keys_str_mv | AT abderrahimoulhaj admissionlevelsofsolubleurokinaseplasminogenactivatorreceptorsuparareassociatedwiththedevelopmentofseverecomplicationsinhospitalisedcovid19patientsaprospectivecohortstudy AT ahmedralsuwaidi admissionlevelsofsolubleurokinaseplasminogenactivatorreceptorsuparareassociatedwiththedevelopmentofseverecomplicationsinhospitalisedcovid19patientsaprospectivecohortstudy AT abubakersuliman admissionlevelsofsolubleurokinaseplasminogenactivatorreceptorsuparareassociatedwiththedevelopmentofseverecomplicationsinhospitalisedcovid19patientsaprospectivecohortstudy AT hudagasmelseed admissionlevelsofsolubleurokinaseplasminogenactivatorreceptorsuparareassociatedwiththedevelopmentofseverecomplicationsinhospitalisedcovid19patientsaprospectivecohortstudy AT shaimakhan admissionlevelsofsolubleurokinaseplasminogenactivatorreceptorsuparareassociatedwiththedevelopmentofseverecomplicationsinhospitalisedcovid19patientsaprospectivecohortstudy AT shammaalawi admissionlevelsofsolubleurokinaseplasminogenactivatorreceptorsuparareassociatedwiththedevelopmentofseverecomplicationsinhospitalisedcovid19patientsaprospectivecohortstudy AT yamanhukan admissionlevelsofsolubleurokinaseplasminogenactivatorreceptorsuparareassociatedwiththedevelopmentofseverecomplicationsinhospitalisedcovid19patientsaprospectivecohortstudy AT junugeorge admissionlevelsofsolubleurokinaseplasminogenactivatorreceptorsuparareassociatedwiththedevelopmentofseverecomplicationsinhospitalisedcovid19patientsaprospectivecohortstudy AT fayezalshamsi admissionlevelsofsolubleurokinaseplasminogenactivatorreceptorsuparareassociatedwiththedevelopmentofseverecomplicationsinhospitalisedcovid19patientsaprospectivecohortstudy AT farrukhsheikh admissionlevelsofsolubleurokinaseplasminogenactivatorreceptorsuparareassociatedwiththedevelopmentofseverecomplicationsinhospitalisedcovid19patientsaprospectivecohortstudy AT zahirosmaneltahirbabiker admissionlevelsofsolubleurokinaseplasminogenactivatorreceptorsuparareassociatedwiththedevelopmentofseverecomplicationsinhospitalisedcovid19patientsaprospectivecohortstudy AT juergenprattes admissionlevelsofsolubleurokinaseplasminogenactivatorreceptorsuparareassociatedwiththedevelopmentofseverecomplicationsinhospitalisedcovid19patientsaprospectivecohortstudy AT haraldsourij admissionlevelsofsolubleurokinaseplasminogenactivatorreceptorsuparareassociatedwiththedevelopmentofseverecomplicationsinhospitalisedcovid19patientsaprospectivecohortstudy |